Prospera Research | Natera

PRODUCT SPOTLIGHT

Global, prospective multicenter study evaluating MMDx and Prospera is now enrolling

IN THE NEWS

New ProActive Registry: largest clinical utility study evaluating Prospera in >3K kidney transplant patients


Setting a new standard through research

Best-in-class transplant care depends on best-in-class assessment. Prospera is the most advanced cfDNA solution for assessing transplant rejection—reinforced by ongoing research efforts:


Sigdel et al Clinical Validation, Published in 2019

  • Conducted with the University of California, San Francisco
  • Largest biopsy-matched study conducted in renal transplantation assessing the use of cell-free DNA
  • The first to publish performance of cell-free DNA testing in subclinical, surveillance setting

Learn more: Sigdel et al Clinical Validation


ProActive Registry Study Now Enrolling

  • Largest clinical utility study evaluating cell-free DNA; includes more than 3,000 kidney transplants studied for three years
  • Long-term assessment of high-risk recipients for up to 5 years post-transplantation
  • Personalized transplant management protocols using cell-free DNA data

Visit the ProActive study


Big Thanks to the Transplant Research Community

  • Natera appreciates the participation of the below leading transplant centers in the ProActive Registry Study. The observational study follows the protocolized use of the Prospera transplant assessment test in 3,000 kidney transplant patients over three to five years.

  • Through our esteemed partners, we hope to generate insights that enable earlier, more precise assessment of allograft rejection to help transplant patients live long and prosper.

ProActive Registry Study Sites now enrolling:1

  • Baylor Scott and White Research Institute
  • Brigham and Women's Hospital
  • California Institute of Renal Research
  • Erie County Medical Center
  • George Washington University Hospital
  • Georgetown University Medical Center
  • Hartford Hospital
  • Henry Ford Health System
  • Intermountain Healthcare
  • Keck School of Medicine USC
  • Legacy Research
  • Lehigh Valley Health Network
  • Loyola University Medical Center
  • Northwell Health, Inc
  • Saint Barnabas Medical Center
  • St. Louis University
  • The Cleveland Clinic Foundation
  • The Regents of the University of California on behalf of its Los Angeles campus
  • The Research Institute at Westchester Medical Center
  • The University of Toledo
  • UT Southwestern
  • University Medical Center Southern Nevada
  • University of California Davis Medical Center
  • University of Florida
  • University of Maryland
  • University of Utah
  • University of Washington Medical Center
  • Wake Forest University Health Sciences
  • Washington University School of Medicine in St. Louis

Research with Molecular Microscope Diagnostic System (MMDx) Now Enrolling

  • Global, prospective multicenter study under the leadership of Dr. Philip Halloran
  • 300 patients to be comprehensively evaluated with clinical information, cell-free DNA measures, biopsies, molecular microscope, evaluations, and donor-specific antibodies (DSA)
  • Integrated data analysis to better inform non-invasive and interventional management in kidney transplantation

References

  1. Accessed: October 9, 2020 from https://clinicaltrials.gov/ct2/show/NCT04091984